WallStreetZenWallStreetZen

NASDAQ: LUMO
Lumos Pharma Inc Stock Forecast, Predictions & Price Target

Analyst price target for LUMO

Based on 4 analysts offering 12 month price targets for Lumos Pharma Inc.
Min Forecast
$4.25-3.74%
Avg Forecast
$9.38+112.34%
Max Forecast
$16.00+262.4%

Should I buy or sell LUMO stock?

Based on 4 analysts offering ratings for Lumos Pharma Inc.
Buy
Strong Buy
1 analysts 25%
Buy
1 analysts 25%
Hold
2 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LUMO stock forecasts and price targets.

LUMO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-10-24
lockedlocked$00.00+00.00%2024-10-23
lockedlocked$00.00+00.00%2024-09-24
lockedlocked$00.00+00.00%2024-08-02

1 of 1

Forecast return on equity

Is LUMO forecast to generate an efficient return?
Company
-69.58%
Industry
151.34%
Market
74.32%
LUMO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LUMO forecast to generate an efficient return on assets?
Company
-33.48%
Industry
25.73%
LUMO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LUMO earnings per share forecast

What is LUMO's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$2.35
Avg 2 year Forecast
-$1.57
Avg 3 year Forecast
-$1.81

LUMO revenue forecast

What is LUMO's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$21.2M+1,326.65%
Avg 2 year Forecast
$1.2M-19.25%
Avg 3 year Forecast
$43.2M+2,809.15%
LUMO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LUMO revenue growth forecast

How is LUMO forecast to perform vs Biotechnology companies and vs the US market?
Company
180.77%
Industry
37.85%
Market
9.43%
LUMO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LUMO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LUMO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LUMO$4.42$9.38+112.34%Buy
LEXX$2.28$10.00+338.60%Buy
LTRN$3.28N/AN/A
NXTC$1.31$6.00+358.02%Buy
CLNN$5.67$60.00+958.20%Strong Buy

Lumos Pharma Stock Forecast FAQ

Is Lumos Pharma Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: LUMO) stock is to Buy LUMO stock.

Out of 4 analysts, 1 (25%) are recommending LUMO as a Strong Buy, 1 (25%) are recommending LUMO as a Buy, 2 (50%) are recommending LUMO as a Hold, 0 (0%) are recommending LUMO as a Sell, and 0 (0%) are recommending LUMO as a Strong Sell.

If you're new to stock investing, here's how to buy Lumos Pharma stock.

What is LUMO's earnings growth forecast for 2024-2026?

(NASDAQ: LUMO) Lumos Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.81%.

Lumos Pharma's earnings in 2024 is -$35,749,000.On average, 2 Wall Street analysts forecast LUMO's earnings for 2024 to be -$19,050,867, with the lowest LUMO earnings forecast at -$33,471,032, and the highest LUMO earnings forecast at -$4,630,701. On average, 2 Wall Street analysts forecast LUMO's earnings for 2025 to be -$12,754,738, with the lowest LUMO earnings forecast at -$16,410,555, and the highest LUMO earnings forecast at -$9,098,921.

In 2026, LUMO is forecast to generate -$14,704,507 in earnings, with the lowest earnings forecast at -$18,604,045 and the highest earnings forecast at -$10,804,969.

What is LUMO's revenue growth forecast for 2024-2026?

(NASDAQ: LUMO) Lumos Pharma's forecast annual revenue growth rate of 180.77% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.85%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.43%.

Lumos Pharma's revenue in 2024 is $1,486,000.On average, 1 Wall Street analysts forecast LUMO's revenue for 2024 to be $172,229,584, with the lowest LUMO revenue forecast at $172,229,584, and the highest LUMO revenue forecast at $172,229,584. On average, 1 Wall Street analysts forecast LUMO's revenue for 2025 to be $9,748,844, with the lowest LUMO revenue forecast at $9,748,844, and the highest LUMO revenue forecast at $9,748,844.

In 2026, LUMO is forecast to generate $351,202,120 in revenue, with the lowest revenue forecast at $351,202,120 and the highest revenue forecast at $351,202,120.

What is LUMO's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: LUMO) forecast ROA is -33.48%, which is lower than the forecast US Biotechnology industry average of 25.73%.

What is LUMO's Price Target?

According to 4 Wall Street analysts that have issued a 1 year LUMO price target, the average LUMO price target is $9.38, with the highest LUMO stock price forecast at $16.00 and the lowest LUMO stock price forecast at $4.25.

On average, Wall Street analysts predict that Lumos Pharma's share price could reach $9.38 by Oct 24, 2025. The average Lumos Pharma stock price prediction forecasts a potential upside of 112.34% from the current LUMO share price of $4.42.

What is LUMO's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: LUMO) Lumos Pharma's current Earnings Per Share (EPS) is -$4.43. On average, analysts forecast that LUMO's EPS will be -$2.35 for 2024, with the lowest EPS forecast at -$4.12, and the highest EPS forecast at -$0.57. On average, analysts forecast that LUMO's EPS will be -$1.57 for 2025, with the lowest EPS forecast at -$2.02, and the highest EPS forecast at -$1.12. In 2026, LUMO's EPS is forecast to hit -$1.81 (min: -$2.29, max: -$1.33).

What is LUMO's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: LUMO) forecast ROE is -69.58%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.